NASDAQ:INSM

Insmed Stock News

Healthcare > Biotechnology

Buy INSM

*Your capital is at risk

$106.92

-0.490 (-0.456%)

At Close: Jul 24, 2026

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

01:46pm, Friday, 09'th May 2025

INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.

Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript

02:55pm, Thursday, 08'th May 2025

Insmed Incorporated (NASDAQ:INSM ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Bryan Dunn - Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bons

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

09:20am, Thursday, 08'th May 2025

Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago.

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

07:00am, Thursday, 08'th May 2025

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in

Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline

11:07am, Thursday, 01'st May 2025

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

11:30am, Tuesday, 29'th Apr 2025

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa

Insmed To Present at the BofA Securities 2025 Health Care Conference

07:00am, Tuesday, 29'th Apr 2025

BRIDGEWATER, N.J. , April 29, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfo

Insmed: Poised For Transformation Beyond ARIKAYCE

11:58am, Friday, 25'th Apr 2025

Insmed's future hinges on the development and launch of its pipeline, particularly brensocatib, despite current financial losses due to strategic investments. Brensocatib shows promising Phase 3 resul

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

07:00am, Thursday, 24'th Apr 2025

BRIDGEWATER, N.J. , April 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfo

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

05:00pm, Wednesday, 23'rd Apr 2025

—Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— �

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

07:00am, Wednesday, 23'rd Apr 2025

BRIDGEWATER, N.J. , April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfo

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

08:00am, Tuesday, 25'th Mar 2025

—New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups— —Data from ASPEN Post-hoc Analysis Evaluating Changes in L

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by